FDA Turns Down Ivonescimab, Delaying Potential Rival to Keytruda

The FDA rejected Summit Therapeutics’ ivonescimab for EGFR-mutated lung cancer after the trial failed to show a clear overall survival benefit.

FDA Turns Down Ivonescimab, Delaying Potential Rival to Keytruda
Credit: Merck
Already have an account? Sign in.